and/or apremilast. This conditional recommendation now includes apremilast, but it is otherwise unchanged from the 2017 guideline. Four observational studies provided additional indirect evidence to the previous systematic literature review and found no relationship between the included drugs and the risk of postoperative infections, although the number of included cases and events were low For patients with RA, AS, PsA, or JIA undergoing elective THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended. This recommendation no longer includes patients with SLE, who are addressed separately (see below for rationale) but has not otherwise changed. Table 2 This recommendation is conditional because the evidence is indirect and there is a lack of a comparator group in the included studies Low For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids